A clinical trial of CAR-T cell therapy in the patients with ovarian cancer
Phase of Trial: Phase I
Latest Information Update: 25 Jan 2019
Price : $35 *
At a glance
- Drugs CAR-T cell therapy Certainty Therapeutics (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions
- 25 Jan 2019 According to an Anixa Biosciences media release, the company expects to file IND in the second calendar quarter of 2019 while the trial is expected to start in July 2019.
- 29 Oct 2018 New trial record
- 22 Oct 2018 According to an Anixa Biosciences media release, Pre-IND meeting has been completed.